Altropane

Drug Profile

Altropane

Alternative Names: 123-I Altropane®; [123I]-E-IACFT Injection; [123I]NAV5001; Altropane; CFT; Iodine-123-E-IACFT Injection; NAV-5001; O 587

Latest Information Update: 22 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Harvard University
  • Developer Alseres Pharmaceuticals
  • Class Contrast media; Esters; Fluorobenzenes; Iodine radioisotopes; Radiopharmaceutical diagnostics; Small molecules; Tropanes
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Parkinsonian disorders
  • Phase II Dementia
  • No development reported Attention-deficit hyperactivity disorder

Most Recent Events

  • 04 Jun 2015 NAV 2001 is still in phase III development for Parkinsonian disorders (Diagnosis) in USA
  • 04 Jun 2015 Altropane® is available for licensing as of 04 Jun 2015. http://www.alseres.com/
  • 27 Apr 2015 Alseres terminates sub-license agreement with Navidea Biopharmaceuticals for NAV 5001
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top